Siltuximab

– Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 – – Deepak L. Bhatt, MD, MPH, MBA and Dipender Gill, MD, PhD join Cardiovascular Scientific Advisory Board – – Company nominates abdominal aortic aneurysm as second cardiovascular indication for pacibekitug, expanding development for inflammation-driven cardiovascular disease – NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today is hosting its Investor Day, beginning at 10 a.m. ET, during which it will outline progress across its pipeline and provide updates on its strategic priorities. “We continue to be laser-focused on our development efforts for pacibekitug in order to maximize the potential of this program,” said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline Bio. “Today’s updates, including the over-enrollment of our TRANQUILITY trial, the expansion of our Cardiovascular Scientific Advisory Board, and the addition of a new indication, reflect the strength of our science, the caliber of our team, and our commitment to redefining standards of care for patients worldwide.” Phase 2 TRANQUILITY Trial ProgressTourmaline today is announcing the over-enrollment of its Phase 2 TRANQUILITY trial, which evaluates quarterly and monthly subcutaneous dosing of pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. A total of 143 patients have been enrolled in the Phase 2 TRANQUILITY trial, as compared to 120 patients originally anticipated. Tourmaline expects to report topline data from this trial in the second quarter of 2025. The TRANQUILITY trial is the starting point of Tourmaline’s clinical development program for pacibekitug for the potential treatment of atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular diseases. If successful, results from the TRANQUILITY trial are expected to position Tourmaline to be Phase 3-ready for ASCVD. Expansion of Cardiovascular Scientific Advisory Board (CV SAB)Tourmaline has expanded its CV SAB with two new appointments: Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI joins as Chair of the Tourmaline CV SAB. Dr. Bhatt is the Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai in New York City. Dr. Bhatt has served as principal investigator for a number of groundbreaking cardiovascular clinical trials, bringing to the CV SAB decades of clinical trial expertise.Dipender Gill, MD, PhD is the CEO of Sequoia Genetics and a specialist in leveraging human genetic evidence for drug development. Dr. Gill adds deep translational insight to Tourmaline’s strategic focus. Indication Expansion in Cardiovascular InflammationTourmaline has nominated abdominal aortic aneurysm (AAA) as an additional indication within its cardiovascular inflammation disease focus for pacibekitug. Tourmaline expects to provide additional details on a planned Phase 2 proof-of-concept trial in AAA after topline results from the Phase 2 TRANQUILITY trial are reported in Q2 2025. Update on Thyroid Eye Disease (TED) Development ProgramIn light of Tourmaline’s focus on cardiovascular inflammation, initiation of a Phase 3 trial in TED will be dependent upon results from the ongoing Phase 2b spiriTED trial. Topline data from the Phase 2b spiriTED trial are expected in the second half of 2025; Tourmaline expects to provide additional information on its future development plans in TED at that time. Investor Day Event InformationTourmaline’s Investor Day will take place on December 10, 2024, beginning at 10 a.m. ET. To register for Tourmaline’s Investor Day, please click here or visit the Events and Presentations section of Tourmaline’s website. A replay of the webcast will be available on Tourmaline’s website following the event. It is recommended that participants register at least 15 minutes in advance of the event. About Tourmaline BioTourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006). For more information about Tourmaline Bio and pacibekitug, please visit https://www.tourmalinebio.com or follow us on LinkedIn or X. About Pacibekitug Pacibekitug (also referred to as TOUR006) is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. Pacibekitug has been previously studied in approximately 450 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is currently developing pacibekitug in atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED) as its first two indications, with plans to expand into abdominal aortic aneurysm (AAA) and additional diseases in the future. Cautionary Note Regarding Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe,” “designed to,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on Tourmaline’s current beliefs and expectations. These forward-looking statements include expectations regarding the development and potential therapeutic benefits of pacibekitug; the timing of initiation, progress and results of Tourmaline’s current and future clinical trials for pacibekitug, including reporting of data therefrom and additional details regarding the planning thereof; the timing of future announcements regarding Tourmaline’s development plans and the content of such announcements; the timing of a planned Phase 2 proof-of-concept clinical trial and of Phase 3 clinical trial readiness; and the timing and potential to expand pacibekitug into additional indications. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Tourmaline’s current or future product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Tourmaline’s current or future product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical trials and clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Tourmaline’s current or future product candidates and/or current or future target indications; the risk that Tourmaline’s current or future product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that Tourmaline anticipates; risks regarding the accuracy of Tourmaline’s estimates of expenses, capital requirements and needs for additional financing; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; unexpected litigation or other disputes; the impacts of macroeconomic conditions Tourmaline’s business, clinical trials and financial position; and other risks and uncertainties that are described in Tourmaline’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) on November 7, 2024 and other filings that Tourmaline makes with the SEC from time to time. Any forward-looking statements speak only as of the date of this press release and are based on information available to Tourmaline as of the date hereof, and Tourmaline assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. Media ContactScient PR Sarah Mishek SMishek@ScientPR.com Investor ContactMeru AdvisorsLee M. Sternlstern@meruadvisors.com

GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2024. Recent Business Updates Therapy Selection Presented study results at the 2024 World Conference on Lung Cancer in September 2024. “Neoadjuvant sintilimab plus chemotherapy could be an optional treatment modality in selected EGFR-mutant NSCLC” and “Distinct Genomic and Immune Microenvironment Features of Solid or Micropapillary Predominant Subtype in Stage I Lung Adenocarcinomas”.Signed a strategic cooperation agreement with MGI Tech Co., Ltd in October 2024, aiming to fully complement each other's platform and technological advantages to further promote the clinical application progress and global business of precision oncology. Pharma Services The companion diagnostic (CDx) for EGFR exon 20 insertion mutation (exon20ins) for sunvozertinib, developed through the collaboration of Burning Rock and Dizal, has been approved by the National Medical Products Administration (NMPA) of China, which marks the first co-developed NGS-based CDx for lung cancer approved by NMPA since the release of the CDx guideline in China. Third Quarter 2024 Financial Results Total revenues were RMB128.6 million (US$18.3 million) for the three months ended September 30, 2024, representing a 0.8% increase from RMB127.6 million for the same period in 2023, the increased revenue of in-hospital business was offset by the decrease of central-lab business, as we transition from central-lab to more in-hospital based testing. Revenue generated from in-hospital business was RMB63.8 million (US$9.1 million) for the three months ended September 30, 2024, representing a 17.0% increase from RMB54.5 million for the same period in 2023, driven by an increase in sales volume.Revenue generated from central laboratory business was RMB40.0 million (US$5.7 million) for the three months ended September 30, 2024, representing a 25.2% decrease from RMB53.5 million for the same period in 2023, primarily attributable to a decrease in the number of tests, as we continued our transition towards in-hospital testing.Revenue generated from pharma research and development services was RMB24.9 million (US$3.5 million) for the three months ended September 30, 2024, representing a 27.1% increase from RMB19.6 million for the same period in 2023, primarily attributable to an increased development and testing services performed for our pharma customers. Cost of revenues was RMB36.8 million (US$5.2 million) for the three months ended September 30, 2024, representing an 11.6% decrease from RMB41.6 million for the same period in 2023, primarily due to (i) a decrease in cost of central laboratory business, which was in line with the decrease in revenue generated from this business; (ii) a decrease in amortization expense for all kinds of business; and (iii) the receipt of a government grant for Guangzhou headquarters building. Gross profit was RMB91.8 million (US$13.1 million) for the three months ended September 30, 2024, representing a 6.9% increase from RMB85.9 million for the same period in 2023. Gross margin was 71.4% for the three months ended September 30, 2024, compared to 67.4% for the same period in 2023. By channel, gross margin of central laboratory business was 83.2% for the three months ended September 30, 2024, compared to 77.6% during the same period in 2023, primarily due to the decreased depreciation and rental cost in relation to our laboratory of Guangzhou headquarters; gross margin of in-hospital business was 73.0% for the three months ended September 30, 2024, compared to 65.1% during the same period in 2023, primarily due to the same reason; gross margin of pharma research and development services was 48.2% for the three months ended September 30, 2024, compared to 45.8% during the same period of 2023. Non-GAAP gross profit, which excludes depreciation and amortization expenses, was RMB97.8 million (US$13.9million) for the three months ended September 30, 2024, representing a 2.8% increase from RMB95.1 million for the same period in 2023. Non-GAAP gross margin was 76.0% for the three months ended September 30, 2024, compared to 74.5% for the same period in 2023. Operating expenses were RMB130.4 million (US$18.6 million) for the three months ended September 30, 2024, representing a 50.7% decrease from RMB264.7 million for the same period in 2023. The decrease was primarily driven by decreases in amortized expense on share-based compensation, budget control measures and headcount reduction to improve the Company’s operating efficiency. Research and development expenses were RMB49.2 million (US$7.0 million) for the three months ended September 30, 2024, representing a 41.3% decrease from RMB83.7 million for the same period in 2023, primarily due to (i) a decrease in staff cost resulted from the reorganization of our research and development department to improve operating efficiency; (ii) a decrease in the expenditure for research projects; (iii) a decrease in amortized expense on share-based compensation; and (iv) a decrease in amortized expenses for office building decoration.Selling and marketing expenses were RMB48.4 million (US$6.9 million) for the three months ended September 30, 2024, representing a 22.3% decrease from RMB62.3 million for the same period in 2023, primarily due to (i) a decrease in staff cost resulted from the reorganization of the sales department and improvement in operating efficiency; (ii) a decrease in conference fee; and (iii) a decrease in entertainment expense.General and administrative expenses were RMB32.9 million (US$4.7 million) for the three months ended September 30, 2024, representing a 72.3% decrease from RMB118.7 million for the same period in 2023, primarily due to (i) a decrease in amortized expense on share-based compensation; (ii) a decrease in amortized expenses for office building decoration; (iii) a decrease in operating lease; and (iv) a decrease in general and administrative personnel’s staff cost. Net loss was RMB35.7 million (US$5.10 million) for the three months ended September 30, 2024, compared to RMB175.0 million for the same period in 2023. Cash, cash equivalents, restricted cash and short-term investments were RMB498.2 million (US$71.0 million) as of September 30, 2024. About Burning Rock Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage. For more information about Burning Rock, please visit: ir.brbiotech.com. Safe Harbor Statement This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. Non-GAAP Measures In evaluating the business, the Company considers and uses non-GAAP measures, such as non-GAAP gross profit and non-GAAP gross margin, as supplemental measures to review and assess operating performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The company defines non-GAAP gross profit as gross profit excluding depreciation and amortization. The company defines non-GAAP gross margin as gross margin excluding depreciation and amortization. The company presents these non-GAAP financial measures because they are used by management to evaluate operating performance and formulate business plans. The company believe non-GAAP gross profit and non-GAAP gross margin excluding non-cash impact of depreciation and amortization reflect the company’s ongoing business operations in a manner that allows more meaningful period-to-period comparisons. Contact: IR@brbiotech.com Selected Operating Data As of September 30, 2023December 31, 2023March 31, 2024June 30, 2024September 30, 2024In-hospital Channel: Pipeline partner hospitals(1)2928282930Contracted partner hospitals(2)5559595961Total number of partner hospitals 84 87 87 8891(1) Refers to hospitals that are in the process of establishing in-hospital laboratories, laboratory equipment procurement or installation, staff training or pilot testing using the Company’s products.(2) Refers to hospitals that have entered into contracts to purchase the Company’s products for use on a recurring basis in their respective in-hospital laboratories the Company helped them establish. Kit revenue is generated from contracted hospitals. Selected Financial Data For the three months ended RevenuesSeptember 30, 2023December 31, 2023March 31, 2024June 30, 2024September 30, 2024 (RMB in thousands)Central laboratory channel53,48151,28847,61448,77339,984 In-hospital channel54,49628,809 57,38759,87263,769 Pharma research and development channel19,58940,98820,62226,88824,891 Total revenues127,566 121,085 125,623 135,533 128,644 For the three months ended Gross profit September 30, 2023December 31, 2023March 31, 2024June 30, 2024September 30, 2024 (RMB in thousands)Central laboratory channel41,48741,88637,00238,42433,262 In-hospital channel35,45912,91039,19244,05846,580 Pharma research and development channel8,97423,3179,50012,95612,004 Total gross profit85,920 78,113 85,694 95,438 91,846 For the three months ended Share-based compensation expensesSeptember 30, 2023December 31, 2023March 31, 2024June 30, 2024September 30, 2024 (RMB in thousands)Cost of revenues680654596464289 Research and development expenses12,16112,40112,28712,0083,180 Selling and marketing expenses2,8481,8165081,2321,917 General and administrative expenses57,70456,47255,99054,4074,732 Total share-based compensation expenses 73,393 71,343 69,381 68,111 10,118 Burning Rock Biotech LimitedUnaudited Condensed Statements of Comprehensive Loss(in thousands, except for number of shares and per share data) For the three months ended September 30, 2023 December 31,2023 March 31, 2024 June 30,2024 September 30, 2024 September 30, 2024 RMB RMB RMB RMB RMB US$ Revenues127,566 121,085 125,623 135,533 128,644 18,331 Cost of revenues(41,646)(42,972)(39,929 )(40,095 )(36,798)(5,243) Gross profit 85,920 78,113 85,694 95,438 91,846 13,088 Operating expenses: Research and development expenses(83,701)(73,119)(65,985)(64,952)(49,150)(7,004) Selling and marketing expenses(62,310)(49,785)(46,856)(48,907)(48,411)(6,899) General and administrative expenses(118,724)(121,533)(98,681)(92,794)(32,874)(4,685) Total operating expenses (264,735) (244,437)(211,522 )(206,653 )(130,435)(18,588) Loss from operations (178,815)(166,324)(125,828 )(111,215)(38,589)(5,500) Interest income4,018 5,539 4,038 3,187 3,173 452 Other income (expense), net(157)160 434 (82)1 - Foreign exchange (loss) gain, net423 (517)(13)262 (129)(18) Loss before income tax (174,531)(161,142)(121,369 )(107,848 )(35,544)(5,066) Income tax expenses (450) (1,071)(180) (190)(201)(29) Net loss (174,981) (162,213)(121,549 )(108,038 )(35,745)(5,095) Net loss attributable to Burning Rock Biotech Limited’s shareholders(174,981)(162,213)(121,549 )(108,038)(35,745)(5,095) Net loss attributable to ordinary shareholders(174,981)(162,213)(121,549 )(108,038)(35,745)(5,095) Loss per share for class A and class B ordinary shares: Class A ordinary shares - basic and diluted(1.71)(1.58)(1.19 )(1.05 )(0.35) (0.05) Class B ordinary shares - basic and diluted (1.71)(1.58)(1.19 )(1.05 ) (0.35) (0.05) Weighted average shares outstanding used in loss per share computation: Class A ordinary shares - basic and diluted85,000,869 85,071,360 85,219,188 85,271,858 85,902,670 85,902,670 Class B ordinary shares - basic and diluted17,324,848 17,324,848 17,324,848 17,324,848 17,324,848 17,324,848 Other comprehensive income (loss), net of tax of nil: Foreign currency translation adjustments(1,955)(3,026)590 940 (4,054)(578) Total comprehensive loss (176,936 )(165,239)(120,959 )(107,098)(39,799)(5,673) Total comprehensive loss attributable to Burning Rock Biotech Limited’s shareholders (176,936)(165,239)(120,959 )(107,098 )(39,799)(5,673) Burning Rock Biotech LimitedUnaudited Condensed Statements of Comprehensive Loss(in thousands, except for number of shares and per share data) For the nine months ended September 30, 2023 September 30, 2024 September 30, 2024 RMBRMBUS$Revenues416,350 389,800 55,546 Cost of revenues(131,236)(116,822)(16,648)Gross profit285,114 272,978 38,898 Operating expenses: Research and development expenses(273,897)(180,087)(25,662)Selling and marketing expenses(197,926)(144,174)(20,545)General and administrative expenses(316,288)(224,349)(31,969)Total operating expenses(788,111)(548,610)(78,176)Loss from operations (502,997)(275,632)(39,278)Interest income12,417 10,398 1,482 Other income, net324 353 50 Foreign exchange gain, net97 120 17 Loss before income tax(490,159)(264,761)(37,729)Income tax expenses(1,317)(571)(81)Net loss(491,476)(265,332)(37,810)Net loss attributable to Burning Rock Biotech Limited’s shareholders(491,476)(265,332)(37,810)Net loss attributable to ordinary shareholders(491,476)(265,332)(37,810)Loss per share for class A and class B ordinary shares: Class A ordinary shares - basic and diluted(4.80)(2.58)(0.37)Class B ordinary shares - basic and diluted(4.80)(2.58)(0.37)Weighted average shares outstanding used in loss per share computation: Class A ordinary shares - basic and diluted85,070,921 85,467,131 85,467,131 Class B ordinary shares - basic and diluted17,324,848 17,324,848 17,324,848 Other comprehensive income (loss), net of tax of nil: Foreign currency translation adjustments7,215 (2,524)(360)Total comprehensive loss(484,261)(267,856)(38,170)Total comprehensive loss attributable to Burning Rock Biotech Limited’s shareholders(484,261)(267,856)(38,170) Burning Rock Biotech LimitedUnaudited Condensed Consolidated Balance Sheets(In thousands) As of December 31, 2023September 30, 2024September 30, 2024 RMB RMBUS$ASSETS Current assets: Cash and cash equivalents615,096497,96970,960Restricted cash12027840Accounts receivable, net126,858166,49123,725Contract assets, net22,74817,7502,529Inventories, net69,02066,4449,468Prepayments and other current assets, net50,25430,6234,364Convertible note receivable-5,320758Total current assets 884,096 784,875 111,844 Non-current assets: Equity method investment33724335Convertible note receivable5,320--Property and equipment, net131,91290,13912,845Operating right-of-use assets12,28499,30114,150Intangible assets, net96452575Other non-current assets5,0889,7221,385Total non-current assets 155,905 199,930 28,490 TOTAL ASSETS 1,040,001 984,805 140,334 Burning Rock Biotech LimitedUnaudited Condensed Consolidated Balance Sheets (Continued)(in thousands) As of December 31, 2023 September 30, 2024 September 30, 2024 RMB RMBUS$LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable18,061 25,213 3,593 Deferred revenue130,537 110,748 15,781 Accrued liabilities and other current liabilities104,935 94,110 13,411 Customer deposits1,197 567 81 Current portion of operating lease liabilities8,634 27,842 3,967 Total current liabilities 263,364 258,480 36,833 Non-current liabilities: Non-current portion of operating lease liabilities3,690 73,055 10,410 Other non-current liabilities4,537 5,104 728 Total non-current liabilities 8,227 78,159 11,138 TOTAL LIABILITIES 271,591 336,639 47,971 Shareholders’ equity: Class A ordinary shares116 118 17 Class B ordinary shares21 21 3 Additional paid-in capital4,849,337 4,996,947 712,059 Treasury stock(65,896)(65,896)(9,390)Accumulated deficits(3,853,635)(4,118,967)(586,948)Accumulated other comprehensive loss(161,533)(164,057)(23,378)Total shareholders’ equity768,410 648,166 92,363 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY1,040,001 984,805 140,334 Burning Rock Biotech LimitedUnaudited Condensed Statements of Cash Flows(in thousands) For the three months ended September 30, 2023September 30, 2024September 30, 2024 RMBRMBUS$Net cash used in operating activities(47,417)(30,278)(4,315)Net cash used in investing activities(1,985)(987)(141)Net cash (used in)/generated from financing activities(45,888)2 - Effect of exchange rate on cash, cash equivalents and restricted cash(1,239)(3,537)(503)Net decrease in cash, cash equivalents and restricted cash (96,529)(34,800)(4,959)Cash, cash equivalents and restricted cash at the beginning of period733,278 533,047 75,959 Cash, cash equivalents and restricted cash at the end of period636,749 498,247 71,000 For the nine months ended September 30, 2023September 30, 2024September 30, 2024 RMBRMBUS$Net cash used in operating activities(239,764)(111,323)(15,863)Net cash used in investing activities(8,972)(3,600)(513)Net cash (used in)/generated from financing activities(46,923)2 - Effect of exchange rate on cash, cash equivalents and restricted cash7,140 (2,048)(292)Net decrease in cash, cash equivalents and restricted cash (288,519)(116,969)(16,668)Cash, cash equivalents and restricted cash at the beginning of period925,268 615,216 87,668 Cash, cash equivalents and restricted cash at the end of period636,749 498,247 71,000 Burning Rock Biotech LimitedReconciliations of GAAP and Non-GAAP Results For the three months ended September 30, 2023 December 31, 2023 March 31, 2024 June 30, 2024 September 30, 2024 (RMB in thousands)Gross profit: Central laboratory channel41,487 41,886 37,002 38,424 33,262 In-hospital channel35,459 12,910 39,192 44,058 46,580 Pharma research and development channel8,974 23,317 9,500 12,956 12,004 Total gross profit85,920 78,113 85,694 95,438 91,846 Add: depreciation and amortization: Central laboratory channel2,550 2,414 1,919 1,226 1,277 In-hospital channel2,751 2,728 1,524 824 798 Pharma research and development channel3,863 3,808 3,856 4,417 3,846 Total depreciation and amortization included in cost of revenues 9,164 8,950 7,299 6,467 5,921 Non-GAAP gross profit： Central laboratory channel44,037 44,300 38,921 39,650 34,539 In-hospital channel38,210 15,638 40,716 44,882 47,378 Pharma research and development channel12,837 27,125 13,356 17,373 15,850 Total non-GAAP gross profit95,084 87,063 92,993 101,905 97,767 Non-GAAP gross margin： Central laboratory channel82.3%86.4%81.7%81.3%86.4%In-hospital channel70.1%54.3%70.9%75.0%74.3%Pharma research and development channel65.5%66.2%64.8%64.6%63.7%Total non-GAAP gross margin74.5%71.9%74.0%75.2%76.0%